STAT1 and STAT3 α/β splice form activation predicts host responses in mouse hepatitis virus type 3 infection

被引:15
作者
Ning, Q
Berger, L
Luo, XP
Yan, WM
Gong, FL
Dennis, J
Levy, G
机构
[1] Tongji Hosp, Div Clin Immunol, Wuhan 430030, Peoples R China
[2] Tongji Med Coll, Inst Immunol, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Wuhan 430074, Peoples R China
[4] Univ Toronto, Fac Med, Toronto, ON, Canada
关键词
STAT; MHV-3; TGF-beta; interferon; T helper cells; cytokines;
D O I
10.1002/jmv.10290
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Signal transducer and activator of transcription 1alpha (STAT1 alpha) is reported to be essential for IFN-gamma and IFN-alpha regulated gene expression, while STAT1beta, an alternate splice-form, mediates only IFN-alpha-dependent gene expression. STAT3 alpha and STAT3 splice forms are also differentially activated in response to cytokines including IL-6 and IL-10. The aim of this study was to investigate whether the STAT activation will predict the host immune response to viral infection and possibly a therapeutic target for the treatment of viral infection. Mouse hepatitis virus type 3 (MHV-3) resistant strain (A/J) and sensitive mouse strains (BalB/cJ) were infected intraperitoneally (i.p.) with 100 plaque form units (pfu) of MHV-3. The mice were sacrificed at the indicated times, and livers and spleens were immediately frozen in liquid nitrogen. Nuclear extracts proteins were detected by immunoblotting. STAT1 and STAT3 activation in spleen increased 24 to 72 hr following MHV-3 infections in both sensitive and resistant mouse strains. However, over this time period, the ratio of activated alpha to beta splice-form for STAT1 and STAT3 increased above 1.0 in resistant A/J mice, while the ratio fell to <0.3 in MHV-3 sensitive Balb/cJ and C3H/HeJ strains. Activated STAT1 α/β and STAT3 α/β ratio in liver were similar in resistant and sensitive mouse strains. Treatment of sensitive Balb/cJ mice with neutralizing anti-TGF-β antibody could increase the STAT1 α/β ratio to <1.0 in spleens, predicting enhanced rates of survival. These results suggested that ratio of activated STAT1 alpha/beta and STAT3 alpha/beta in mixed leukocytes from spleen predict the outcome to MHV-3 infection, and may be an important marker and therapeutic target for modification of host immune response to virus infection.
引用
收藏
页码:306 / 312
页数:7
相关论文
共 27 条
[1]   Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells [J].
Chakraborty, A ;
White, SM ;
Schaefer, TS ;
Ball, ED ;
Dyer, KF ;
Tweardy, DJ .
BLOOD, 1996, 88 (07) :2442-2449
[2]  
CHUNG S, 1994, IMMUNOLOGY, V83, P353
[3]   AIDS therapy - Failure isn't what it used to be ... but neither is success [J].
Cohen, J .
SCIENCE, 1998, 279 (5354) :1133-1134
[4]   STATs and gene regulation [J].
Darnell, JE .
SCIENCE, 1997, 277 (5332) :1630-1635
[5]   Fulminant hepatic failure in murine hepatitis virus strain 3 infection: Tissue-specific expression of a novel fgl2 prothrombinase [J].
Ding, JW ;
Ning, Q ;
Liu, MF ;
Lai, A ;
Leibowitz, J ;
Peltekian, KM ;
Cole, EH ;
Fung, LS ;
Holloway, C ;
Marsden, PA ;
Yeger, H ;
Phillips, MJ ;
Levy, GA .
JOURNAL OF VIROLOGY, 1997, 71 (12) :9223-9230
[6]   Design and application of a cytokine-receptor-based interaction trap [J].
Eyckerman, S ;
Verhee, A ;
Van der Heyden, J ;
Lemmens, I ;
Van Ostade, X ;
Vandekerckhove, J ;
Tavernier, J .
NATURE CELL BIOLOGY, 2001, 3 (12) :1114-1119
[7]   Intracellular signalling and antiviral effects of interferons [J].
Heim, MH .
DIGESTIVE AND LIVER DISEASE, 2000, 32 (03) :257-263
[8]   The treatment of chronic viral hepatitis [J].
Hoofnagle, JH ;
DiBisceglie, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (05) :347-356
[9]   Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6 [J].
Ishikawa, H ;
Tsuyama, N ;
Abroun, S ;
Liu, SQ ;
Li, FJ ;
Taniguchi, O ;
Kawano, MM .
BLOOD, 2002, 99 (06) :2172-2178
[10]   Immunology of hepatitis B infection [J].
Jung, MC ;
Pape, GR .
LANCET INFECTIOUS DISEASES, 2002, 2 (01) :43-50